Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $15.65 (market cap $6.91B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 4× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 68 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| NCLH | NUVB | |
|---|---|---|
Market Cap | $6.91B | $1.71B |
Volume | 25,654,210 | 5,448,712 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $9.54 |
52-Week Low | $14.12 | $3.41 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $21.73B | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.05, down 2.97% today, with neutral technical signals and strong analyst support. The company shows improving fundamentals with revenue growth from $9.5B in 2024 to $9.83B in 2025, though net income declined to $423M. Recent Q2 2026 earnings beat expectations at $0.48 EPS versus $0.41 expected, while management expects Q3 results to exceed guidance. Valuation remains attractive with P/E of 9.12 and P/S of 0.72.
NCLH presents a compelling value opportunity with analyst consensus price target of $20.86 offering 38% upside potential. However, investors face risks from persistent yield pressure, high debt levels ($11.78B long-term), and Caribbean pricing competition. The stock's outlook depends on successful execution of earlier booking strategies and maintaining EBITDA growth amid industry headwinds through 2027.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
